Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Shabana Karim

Greenville, MS Medical Doctor

NPI 1992903355 CMS profile 135950

1502 S Colorado St, Greenville, MS 38703

Open in the dashboard

General payments

$12,215

710 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Shabana Karim of Greenville, MS is reported in the CMS Open Payments database as having received $12,215 across 710 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,619 85
2024 General $1,587 83
2023 General $1,782 101
2022 General $1,930 106
2021 General $2,095 131
2020 General $1,557 105
2019 General $1,646 99

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Shabana Karim
  • Mississippi median
  • Middle half of Mississippi
  • National median

In program year 2025, general payments to Shabana Karim were reported at $1,619. Among 9,842 Mississippi profiles paid that year, the median was $175 and the middle half received between $52 and $584.

Show as a table
Year Shabana Karim Mississippi median Middle half National median
2019 $1,646 $180 $57–$617 $163
2020 $1,557 $121 $39–$395 $114
2021 $2,095 $149 $40–$500 $132
2022 $1,930 $161 $43–$537 $149
2023 $1,782 $161 $47–$539 $160
2024 $1,587 $174 $51–$565 $164
2025 $1,619 $175 $52–$584 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Amgen Inc. $3,056 158 payments
  2. AbbVie, Inc. $1,858 114 payments
  3. UCB, Inc. $1,119 68 payments
  4. Pfizer Inc. $816 55 payments
  5. Mallinckrodt Hospital Products Inc. $799 52 payments
  6. Janssen Biotech, Inc. $648 37 payments
  7. Novartis Pharmaceuticals Corporation $536 29 payments
  8. Aurinia Pharma U.S., Inc. $498 25 payments
  9. GlaxoSmithKline, LLC. $493 33 payments
  10. AstraZeneca Pharmaceuticals LP $376 23 payments
  11. Other $2,015 116 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $12,130 704 payments
  2. Education $85 6 payments
Products named General payments · program years 2019–2025
  1. RINVOQ $1,141 71 payments
  2. Prolia $951 57 payments
  3. Cimzia $920 58 payments
  4. Enbrel Inflammation $895 43 payments
  5. ACTHAR $799 52 payments
  6. Otezla $774 36 payments
  7. XELJANZ $725 49 payments
  8. EVENITY $644 39 payments
  9. Enbrel Inflammation $542 25 payments
  10. COSENTYX $538 28 payments
  11. Other $7,417 426 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 56 drugs

Part D claims

4,511

Median for Rheumatology: 1,511

Drug cost

$4,977,063

Median for Rheumatology: $1,139,948

Branded share of claims

49.5%

Median for Rheumatology: 28.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Xeljanz Xr Tofacitinib Citrate Brand 151 $908,183
Rinvoq Upadacitinib Brand 113 $728,179
Humira(Cf) Pen Adalimumab Brand 56 $449,554
Enbrel Sureclick Etanercept Brand 58 $439,846
Benlysta Belimumab Brand 86 $433,454
Cimzia (2 Pack) Certolizumab Pegol Brand 67 $387,244
Enbrel Mini Etanercept Brand 47 $370,802
Orencia Clickject Abatacept Brand 34 $194,664
Humira Pen Adalimumab Brand 18 $177,274
Orencia Abatacept/Maltose Brand 31 $144,475

The 10 drugs with the highest cost, of 56 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 5,224 Part D prescribers listed as Rheumatology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 25 billing codes

Paid by Medicare

$146,037

Of which drugs: $39,683

Medicare patients

281

Average age 74

Services billed

7,209

219 women, 62 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Diabetes 37%
Heart failure 34%
Chronic kidney disease 27%
Ischemic heart disease 26%
Osteoporosis 26%
COPD 24%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, denosumab, 1 mg J0897 Office 16 1,440 $29,441
Injection, methylprednisolone acetate, 1 mg J1010 Office 17 1,300 $129
Injection, ketorolac tromethamine, per 15 mg J1885 Office 15 84 $46

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 22 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Enbrel
  • Amgen Inc. $170
$170 105 —
ACTHAR
  • Mallinckrodt Hospital Products Inc. $155
$155 — —
RINVOQ
  • AbbVie, Inc. $145
$145 113 —
Cimzia
  • UCB, Inc. $135
$135 67 —
LUPKYNIS
  • Aurinia Pharma U.S., Inc. $127
$127 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 22 in the dashboard with a free account

Records

710 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record